Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma
ALS Chang, AE Oro - Archives of dermatology, 2012 - jamanetwork.com
Methods. We conducted a retrospective medical chart review, approved by the Stanford
human subjects panel, examining the records of 28 consequent patients with laBCC or
mBCC treated with continuous administration of vismodegib and observed from 4 to 162
weeks (until any-cause death or last clinic visit). All patients were seen at Stanford Hospital
and Clinics on a monthly basis. All patients had been enrolled as part of 3 vismodegib
clinical trials with identical inclusion and exclusion criteria (NCT00833417, NCT00959647 …
human subjects panel, examining the records of 28 consequent patients with laBCC or
mBCC treated with continuous administration of vismodegib and observed from 4 to 162
weeks (until any-cause death or last clinic visit). All patients were seen at Stanford Hospital
and Clinics on a monthly basis. All patients had been enrolled as part of 3 vismodegib
clinical trials with identical inclusion and exclusion criteria (NCT00833417, NCT00959647 …